Biohaven is a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases. Biohaven's experienced management team brings with it a track record of delivering new drug approvals for products for diseases such as migraine, depression, bipolar and schizophrenia. The company is advancing a pipeline of therapies for diseases, many of which have limited or no treatment options, leveraging its proven drug development capabilities and proprietary platforms, including Kv7 ion channel modulation for epilepsy and neuronal hyperexcitability, glutamate modulation for obsessive-compulsive disorder and spinocerebellar ataxia, myostatin inhibition for neuromuscular diseases and metabolic disorders, and brain-penetrant TYK2/JAK1 inhibition for neuroinflammatory disorders. Biohaven's portfolio of early- and late-stage product candidates also includes discovery research programs focused on TRPM3 channel activation for neuropathic pain, CD-38 antibody recruiting, bispecific molecules for multiple myeloma, antibody drug conjugates (ADCs), and targeted extracellular protein degradation platform technology (MoDE™) with potential application in neurological disorders, cancer, and autoimmune diseases.
Company profile
Ticker
BHVN
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Biohaven Research Ltd.
SEC CIK
Corporate docs
Subsidiaries
Biohaven Specialty Pharmaceutical Ltd. • Biohaven Therapeutics Ltd. • Biohaven Pharmaceuticals, Inc. • BioShin Limited • BioShin Hong Kong Limited • BioShin (Shanghai) Consulting Services Co., Limited • Biohaven Bioscience Ireland Limited • Biohaven Therapeutics IP Ltd. • Biohaven CGRP IP Ltd. • BioShin (Singapore) PTE. LTD. ...
Latest filings (excl ownership)
8-K
Other Events
22 Apr 24
424B5
Prospectus supplement for primary offering
19 Apr 24
424B5
Prospectus supplement for primary offering
17 Apr 24
8-K
Regulation FD Disclosure
15 Apr 24
DEFA14A
Additional proxy soliciting materials
18 Mar 24
DEF 14A
Definitive proxy
18 Mar 24
8-K
Other Events
12 Mar 24
424B7
Prospectus with selling stockholder info
12 Mar 24
8-K
Biohaven Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Developments
29 Feb 24
10-K
2023 FY
Annual report
29 Feb 24
Latest ownership filings
4
Gregory Bailey
23 Apr 24
4
JOHN W CHILDS
23 Apr 24
4
Vlad Coric
23 Apr 24
4
JOHN W CHILDS
5 Apr 24
4
Vlad Coric
5 Apr 24
4
JOHN W CHILDS
8 Mar 24
4
Vlad Coric
8 Mar 24
SC 13G/A
Point72 Asset Management, L.P.
14 Feb 24
SC 13G/A
SUVRETTA CAPITAL MANAGEMENT, LLC
13 Feb 24
SC 13G/A
JANUS HENDERSON GROUP PLC
13 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | |
---|---|---|
Revenue | ||
Cost of revenue | ||
Operating income | ||
Operating margin | ||
Net income | ||
Net profit margin | ||
Cash on hand | ||
Change in cash | ||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 125.99 mm | 125.99 mm | 125.99 mm | 125.99 mm | 125.99 mm | 125.99 mm |
Cash burn (monthly) | 25.32 mm | (no burn) | 36.85 mm | 41.47 mm | (no burn) | (no burn) |
Cash used (since last report) | 173.34 mm | n/a | 252.27 mm | 283.88 mm | n/a | n/a |
Cash remaining | -47.35 mm | n/a | -126.28 mm | -157.89 mm | n/a | n/a |
Runway (months of cash) | -1.9 | n/a | -3.4 | -3.8 | n/a | n/a |
Institutional ownership, Q3 2023
75.1% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 187 |
Opened positions | 22 |
Closed positions | 25 |
Increased positions | 62 |
Reduced positions | 67 |
13F shares | Current |
---|---|
Total value | 1.59 tn |
Total shares | 61.43 mm |
Total puts | 689.45 k |
Total calls | 380.75 k |
Total put/call ratio | 1.8 |
Largest owners | Shares | Value |
---|---|---|
SF Stifel Financial | 5.77 mm | $150.07 bn |
JHG Janus Henderson | 5.33 mm | $138.51 bn |
BLK Blackrock | 4.24 mm | $110.31 bn |
Suvretta Capital Management | 4.01 mm | $104.19 bn |
STT State Street | 3.96 mm | $103.04 bn |
FMR | 3.26 mm | $84.77 bn |
RP Management | 2.94 mm | $76.38 bn |
T. Rowe Price | 2.34 mm | $61.05 bn |
Armistice Capital | 2.04 mm | $52.96 bn |
Holocene Advisors | 1.97 mm | $51.23 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
22 Apr 24 | Childs John W | Common Shares | Buy | Acquire P | Yes | No | 41 | 73,170 | 3.00 mm | 2,254,841 |
22 Apr 24 | Childs John W | Common Shares | Buy | Acquire P | Yes | No | 41 | 97,560 | 4.00 mm | 4,096,512 |
22 Apr 24 | Childs John W | Common Shares | Buy | Acquire P | Yes | No | 41 | 24,391 | 1.00 mm | 24,391 |
22 Apr 24 | Coric Vlad | Common Shares | Buy | Acquire P | No | No | 41 | 121,951 | 5.00 mm | 1,788,417 |
22 Apr 24 | Bailey Gregory | Common Shares | Buy | Acquire P | No | No | 41 | 48,780 | 2.00 mm | 1,574,568 |
5 Apr 24 | Coric Vlad | Common Shares | Grant | Acquire A | Yes | No | 0 | 231 | 0.00 | 407,213 |
5 Apr 24 | Coric Vlad | Common Shares | Grant | Acquire A | Yes | No | 0 | 231 | 0.00 | 840,890 |
5 Apr 24 | Coric Vlad | Common Shares | Grant | Acquire A | No | No | 0 | 232 | 0.00 | 1,666,466 |
5 Apr 24 | Childs John W | Common Shares | Grant | Acquire A | Yes | No | 0 | 2,091 | 0.00 | 2,181,671 |
News
UBS Maintains Buy on Biohaven, Raises Price Target to $60
23 Apr 24
Cantor Fitzgerald Reiterates Overweight on Biohaven
18 Apr 24
Biohaven Reports Pricing Of Public Offering Of 5.609M Of Its Common Shares At $41 Per Share
18 Apr 24
Biohaven Announces $200M Public Offering Of Common Shares
17 Apr 24
Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session
15 Apr 24
Press releases
Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
22 Apr 24
Biohaven Announces Pricing of $230 Million Public Offering of Common Shares
18 Apr 24
Biohaven Announces Proposed Public Offering of Common Shares
17 Apr 24
Biohaven Showcases Innovative Neuroscience Portfolio with 20 Presentations at the 2024 American Academy of Neurology (AAN) Annual Meeting and Provides Other Business Updates
13 Apr 24